In recent developments, HC Wainwright & Co. has made adjustments to its price target for Jasper Therapeutics (JSPR, Financial). The price target has been lowered from the prior value of $40.00 to a new target of $20.00. This adjustment represents a 50% decrease in the price target.
Despite the lowered price target, the analyst, Emily Bodnar, maintains a "Buy" rating for Jasper Therapeutics (JSPR, Financial), consistent with the previous rating. This suggests continued confidence in the company's potential, albeit at a revised valuation level.
The report, dated July 7, 2025, indicates that the assessment by HC Wainwright & Co. reflects updated considerations of market conditions and company performance. Investors in Jasper Therapeutics (JSPR, Financial) should take note of these changes and adjust their expectations accordingly.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $47.88 with a high estimate of $70.00 and a low estimate of $15.00. The average target implies an upside of 1,474.84% from the current price of $3.04. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
